Apr 18 |
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
|
Apr 18 |
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
|
Apr 18 |
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
|
Mar 6 |
Cerevel Therapeutics: Parkinson's Could Be The Issue
|
Feb 16 |
Cerevel, AbbVie get FTC Second Requests for more merger info
|
Feb 6 |
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
|
Jan 29 |
AbbVie raised to Outperform at William Blair ahead of earnings
|
Dec 29 |
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
|
Dec 8 |
AbbVie – Cerevel deal reportedly followed unusual options trading
|
Dec 8 |
$19 Billion in a Week: AbbVie Makes Two Big Bets
|